朱书雷

2015-09至2020-07，华东师范大学，有机化学，博士

2023-10至今，华东师范大学，人工智能新药创智中心，副教授

2020-07至2023-09，华东师范大学，博士后（合作导师：吕伟研究员）

朱书雷，华东师范大学药学院副教授，硕士生导师。目前从事抗肿瘤药物以及衰老疾病药物的设计与递送工作，致力于开发抗肿瘤药物和衰老相关疾病药物应用的新方法和新技术，解决药物脱靶与在靶毒性问题。通过构建新型酶活前药疗法，成功开发出若干新型高效的临床候选药物，已与多个医药公司达成合作，实现科研成果转化。目前，共同设计开发的Linker-Payload平台已应用于包括前药（prodrug）、抗体药物偶联物（ADC）、小分子药物偶联物（SMDC）、多肽药物偶联物（PDC）等体系。基于该平台的抗体药物偶联物，已经获得多个临床批件。另外，有多个候选分子处于临床前研究中。以第一/通讯作者在J. Control. Release, Asian J. Pharm. Sci., J. Med. Chem., Eur. J. Med. Chem.等期刊发表SCI论文20余篇；申请发明专利10项；主持和参与国家自然科学基金青年基金项目1项和企业横向合作项目若干项；担任J. Med.Chem., Eur. J. Med. Chem., Int. J. Nanomed.等期刊审稿人。

1）中国药学会会员；

2）中国化学会会员；

3）上海市药学会会员；

课题组科研方向丰富，经费充足，气氛融洽，欢迎报考！

1. 新型多方式激活药物偶联物

2. 衰老相关疾病新药发现

3. 新型药物递送系统

1. 国家自然科学基金委员会，青年科学基金项目，基于胞外HSP90配体的药物偶联物传递系统，82104000，2020-01至2022-12。

2. 企业合作项目，抗体偶联药物linker-payload研究，2023-12至2024-12。

3. 企业合作项目，ADC毒素-喜树碱类分子联合研究，2022-07至2026-12。

4. 企业合作项目，新型连接子技术联合研究，2024-05至2029-12。

5. 企业合作项目，氘代喜树碱类分子联合研究，2022-12至2030-12。

代表性成果

1.         Zhang, Y. F.; Wang, L.; Cao, X. M.; Song, R. W.; Yin, S. C.; Cheng, Z. Y.; Li, W. N.; Shen, K. Y.; Zhao, T.; Xu, J.; Liu, S. X.; Xie, Q.; Wu, Y. H.; Gao, B.; Guo, Q. S.; Wu, J. S.; Qiu, X. F.; Wang, B. X.; Zhang, W. B.; Yang, T.; Lu, W.; Zhu, S. L.* Evaluation of Double Self-Immolative Linker-Based Antibody–Drug Conjugate FDA022 BB05 with Enhanced Therapeutic Potential. Journal of Medicinal Chemistry, 2024, accepted.

2.         Guo, Q. S.; Gao, B.; Song, R. W.; Li, W. N.; Zhu, S. L.; Xie, Q.; Lou, S. S.; Wang, L.; Shen, J. F.; Zhao, T.; Zhang, Y. F.; Wu, J. S.; Lu, W.; Yang, T. FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Molecular Cancer Therapeutics, 2024, 23, 1367-1377.

3.         Li, Y. L.; Cheng, Z. Y.; Zhou, W.; Wang, L.; Li, X. M.; Xia, G. X.; Lu, W.; Zhu, S. L.* Synthesis and evaluation of homocamptothecin antibody-drug conjugates for cancer treatment. European Journal of Medicinal Chemistry, 2024, 279, 116899.

4.         Jiang, X.; Zhu, L. Y.; Wei, Q. Y.; Lu, W.; Yu, J. H.; Zhu, S. L.* Enhancing SN38 prodrug delivery using a self-immolative linker and endogenous albumin transport. Journal of Controlled Release, 2024, 369, 622-629.

5.         Lu, Y. X.; Huang, Y., Jin, J. Y.; Yu, J. H.; Lu, W., Zhu, S. L.*. Design, synthesis, and biological evaluation of cathepsin B cleavage albumin-binding SN38 prodrug in breast cancer. Bioorganic Chemistry, 2024, 147, 107370.

6.         Cao, Y. T.; Shen, Q. Q.; Ding, M. Y.; Lu, W.; Zhu, S. L.* Development of HSP90 inhibitors-SN38 conjugates for cancer treatment. Bioorganic Chemistry, 2023, 137, 106582.

7.         Ding, M. Y.; Zhu, Q. W.; Lu, W.; Zhu, S. L.*. Design and synthesis of multivalent drug delivery system with CA IX inhibitors as ligands. Bioorganic & Medicinal Chemistry, 2023, 93, 117456.

8.         Sun, L.; Zhang, J. F.; Zhou, J. E.; Wang, J.; Wang, Z. H.; Luo, Y. Y.; Zhu, S. L.*; Yang, F.; Tang, J.; Lu, W.; Wang, Y. T.; Yu, L.; Yan, Z. Q*. Monitoring the in vivo siRNA release from lipid nanoparticles based on the fluorescence resonance energy transfer principle. Asian Journal of Pharmaceutical Sciences, 2023, 18, 100769.

9.         Ding, M. Y.; Shao, Y. Y.; Sun, D. W.; Meng, S. R.; Zang, Y.; Zhou, Y. B.; Li, J.; Lu, W.; Zhu, S. L.* Design, synthesis, and biological evaluation of BRD4 degraders. Bioorganic & Medicinal Chemistry, 2022, 78, 117134.

10.     Zhu, S. L.; Liu, J. Y.; Xiao, D. H.; Wang, P. P.; Ma, J. K.; Hu, X. B.; Fu, J. F.; Zhou, Y. B.*; Li, J.*; Lu, W*. Design, synthesis, and biological evaluation of Wee1 kinase degraders. European Journal of Medicinal Chemistry,2022, 243, 114786.

11.     Zhu, S. L.; Lu, Y. X.; Jin, J. Y.*; Yu, J. H.; Lu, W*. An HSP90 inhibitor based fluorescent probe for selective tumor targeting. Dyes and Pigments, 2021, 196, 109783.

12.     Zhu, S. L.; Li, Y. L.; Huang, Y. S.; Zhang, M. M.; Gu, X. F.; He, Y.; Liu, H. C.; Ma, M. L.*; Lu, W*. Optimized HSP90 mediated fluorescent probes for cancer-specific bioimaging. Journal of Materials Chemistry B, 2020, 8, 1878-1896.

13.     Zhu, S. L.; Yu, X. M.; He, Y.; Ma, M. L.*; Lu, W*. Synthesis and fluorescent studies of a low molecular weight rotor for living cancer cell imaging. Dyes and Pigments, 2020, 178, 108353.

14.     Zhu, S. L.; Shen, Q. Q.; Gao, Y. L.; Wang, L.; Fang, Y. F.*; Chen, Y.; Lu, W*. Design, synthesis and biological evaluation of HSP90 inhibitor-SN38 conjugates for targeted drug accumulation. Journal of Medicinal Chemistry, 2020, 63, 5421-5441.

15.     Zhen, Z.#; Zhu, S. L.#; Jin, J. Y.; Wang, L.*; Lu, W*. A water-soluble probe with p-hydrobenzyl quaternary ammonium linker for selective imaging in senescent cells. Analytica Chimica Acta, 2020, 1133, 99-108.

16.     Lu, Y. X.; Sun, D. W.; Xiao, D. H.; Shao, Y. Y.; Su, M. B.; Zhou, Y. B.; Li, J.; Zhu, S. L.*; Lu, W*. Design, synthesis and biological evaluation of HDAC degraders with CRBN E3 ligase ligands. Molecules, 2021, 26, 7241.

17.     He, T. T.; Zhu, S. L.*; Lu, W*. Design, synthesis and biological evaluation of 4-(1H-1,2,3-triazol-1-yl)benzamides as HSP90 inhibitors. Molecular Diversity, 2023, 27, 239-248.

18.     Ding, M. Y.; Shen, Q. Q.; Lu, W*; Zhu, S. L.*. Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment. Molecular Diversity, 2023, 1-20.

19.     Zhang, Y.; Ding, M.; Wang, L.; Yin, S.; Zhang, L.; Cao, X.; Zhu, S. L.*; Yang, T. Synthesis and biological evaluation of novel quaternary ammonium antibody drug conjugates based on camptothecin derivatives. Plos one, 2023, 18(12), e0292871.

20.     Huang, Y.; Zhang, W.; Xu, Y. Y.; Zhu, S. L.; Wu, Y. Q.; Chen, T.; Yu, J. Dynamic core crosslinked camptothecin prodrug micelles with reduction sensitivity and boronic acid-mediated enhanced endocytosis: An intelligent tumor-targeted delivery nanoplatform. International Journal of Pharmaceutics, 2020, 580, 119250.

21.     Cheng, Z.; Huang, Y.; Shao, P.; Wang, L.; Zhu, S. L.; Yu, J.; Lu, W. Hypoxia-activated albumin-binding exatecan prodrug for cancer therapy. ACS omega, 2021, 7(1), 1082-1089.